Since the first reports of SARS-CoV-2 infections in China, doctors, parents and policy-makers
have been aware that COVID-19 is ‘not just another respiratory virus’ in children. There is a …

Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …

Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …

Important questions remain unanswered regarding why children have mild disease
compared with adults; how children of different ages contribute to asymptomatic community …

Background Some high-income countries have deployed fourth doses of COVID-19 vaccines,
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …

Objectives To evaluate the persistence of immunogenicity three months after third dose
boosters. Methods COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven …

Some 8.8 million schoolchildren in the UK have experienced severe disruption to their
education, with prolonged school closures and national exams cancelled for two consecutive …

Despite being responsible for significant global infant morbidity and mortality, until recently
there have been no effective therapeutics available for healthy infants to protect them from …

Background Priming COVID-19 vaccine schedules have been deployed at variable intervals
globally, which might influence immune persistence and the relative importance of third-…